PortalPublikationenImpact of disease progression on health-related quality of l...

Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry

Standard

Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry. / Müller, Volkmar; Nabieva, Naiba; Häberle, Lothar; Taran, Florin-Andrei; Hartkopf, Andreas D; Volz, Bernhard; Overkamp, Friedrich; Brandl, Anna Lisa; Kolberg, Hans-Christian; Hadji, Peyman; Tesch, Hans; Ettl, Johannes; Lux, Michael P; Lüftner, Diana; Belleville, Erik; Fasching, Peter A; Janni, Wolfgang; Beckmann, Matthias W; Wimberger, Pauline; Hielscher, Carsten; Fehm, Tanja N; Brucker, Sara Y; Wallwiener, Diethelm; Schneeweiss, Andreas; Wallwiener, Markus.

in: BREAST, Jahrgang 37, 02.2018, S. 154-160.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Müller, V, Nabieva, N, Häberle, L, Taran, F-A, Hartkopf, AD, Volz, B, Overkamp, F, Brandl, AL, Kolberg, H-C, Hadji, P, Tesch, H, Ettl, J, Lux, MP, Lüftner, D, Belleville, E, Fasching, PA, Janni, W, Beckmann, MW, Wimberger, P, Hielscher, C, Fehm, TN, Brucker, SY, Wallwiener, D, Schneeweiss, A & Wallwiener, M 2018, 'Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry', BREAST, Jg. 37, S. 154-160. https://doi.org/10.1016/j.breast.2017.08.008

APA

Müller, V., Nabieva, N., Häberle, L., Taran, F-A., Hartkopf, A. D., Volz, B., Overkamp, F., Brandl, A. L., Kolberg, H-C., Hadji, P., Tesch, H., Ettl, J., Lux, M. P., Lüftner, D., Belleville, E., Fasching, P. A., Janni, W., Beckmann, M. W., Wimberger, P., ... Wallwiener, M. (2018). Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry. BREAST, 37, 154-160. https://doi.org/10.1016/j.breast.2017.08.008

Vancouver

Müller V, Nabieva N, Häberle L, Taran F-A, Hartkopf AD, Volz B et al. Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry. BREAST. 2018 Feb;37:154-160. https://doi.org/10.1016/j.breast.2017.08.008

Bibtex

@article{1cc9dda57b3b458aa0dcbd938c4b1d1a,
title = "Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry",
abstract = "OBJECTIVES: Improved progression-free survival is considered as treatment goal for patients with metastatic breast cancer (MBC) since it is assumed to delay or prevent deterioration of quality of life. Aim of our analysis was to examine the influence of disease progression on health-related quality of life (HRQoL).MATERIALS AND METHODS: The PRAEGNANT study comprises a real-life registry for patients with MBC. HRQoL was assessed with the EORTC-QLQ-C30 Version 3.0 questionnaire at study entry and every 3 months thereafter. The primary endpoint was minimally important deterioration (MID) in global HRQoL score by ≥ five points between baseline and any follow-up assessment. A logistic regression model was built with MID (yes/no) at a follow-up timepoint as outcome variable and several covariates as predictors.RESULTS: In total, 329 patients were included in this analysis, with disease progression in 63 patients. Concerning the primary study aim, progression status predicted MID of global HRQoL status in addition to the other covariates. The adjusted odds ratio for the effect of progression status on MID was 2.22 (95% CI: 1.04 - 4.73). Comparisons of mean differences of QoL domains/scales yielded no differences.CONCLUSIONS: We provide evidence that disease progression in patients with metastatic breast cancer in a real-world registry has a significant negative impact on HRQoL as measured by MID of HRQoL. This study emphasizes the relevance of avoiding progression and prolonging PFS to maintain QoL.",
keywords = "Journal Article",
author = "Volkmar M{\"u}ller and Naiba Nabieva and Lothar H{\"a}berle and Florin-Andrei Taran and Hartkopf, {Andreas D} and Bernhard Volz and Friedrich Overkamp and Brandl, {Anna Lisa} and Hans-Christian Kolberg and Peyman Hadji and Hans Tesch and Johannes Ettl and Lux, {Michael P} and Diana L{\"u}ftner and Erik Belleville and Fasching, {Peter A} and Wolfgang Janni and Beckmann, {Matthias W} and Pauline Wimberger and Carsten Hielscher and Fehm, {Tanja N} and Brucker, {Sara Y} and Diethelm Wallwiener and Andreas Schneeweiss and Markus Wallwiener",
note = "Copyright {\textcopyright} 2017 Elsevier Ltd. All rights reserved.",
year = "2018",
month = feb,
doi = "10.1016/j.breast.2017.08.008",
language = "English",
volume = "37",
pages = "154--160",
journal = "BREAST",
issn = "0960-9776",
publisher = "Churchill Livingstone",

}

RIS

TY - JOUR

T1 - Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry

AU - Müller, Volkmar

AU - Nabieva, Naiba

AU - Häberle, Lothar

AU - Taran, Florin-Andrei

AU - Hartkopf, Andreas D

AU - Volz, Bernhard

AU - Overkamp, Friedrich

AU - Brandl, Anna Lisa

AU - Kolberg, Hans-Christian

AU - Hadji, Peyman

AU - Tesch, Hans

AU - Ettl, Johannes

AU - Lux, Michael P

AU - Lüftner, Diana

AU - Belleville, Erik

AU - Fasching, Peter A

AU - Janni, Wolfgang

AU - Beckmann, Matthias W

AU - Wimberger, Pauline

AU - Hielscher, Carsten

AU - Fehm, Tanja N

AU - Brucker, Sara Y

AU - Wallwiener, Diethelm

AU - Schneeweiss, Andreas

AU - Wallwiener, Markus

N1 - Copyright © 2017 Elsevier Ltd. All rights reserved.

PY - 2018/2

Y1 - 2018/2

N2 - OBJECTIVES: Improved progression-free survival is considered as treatment goal for patients with metastatic breast cancer (MBC) since it is assumed to delay or prevent deterioration of quality of life. Aim of our analysis was to examine the influence of disease progression on health-related quality of life (HRQoL).MATERIALS AND METHODS: The PRAEGNANT study comprises a real-life registry for patients with MBC. HRQoL was assessed with the EORTC-QLQ-C30 Version 3.0 questionnaire at study entry and every 3 months thereafter. The primary endpoint was minimally important deterioration (MID) in global HRQoL score by ≥ five points between baseline and any follow-up assessment. A logistic regression model was built with MID (yes/no) at a follow-up timepoint as outcome variable and several covariates as predictors.RESULTS: In total, 329 patients were included in this analysis, with disease progression in 63 patients. Concerning the primary study aim, progression status predicted MID of global HRQoL status in addition to the other covariates. The adjusted odds ratio for the effect of progression status on MID was 2.22 (95% CI: 1.04 - 4.73). Comparisons of mean differences of QoL domains/scales yielded no differences.CONCLUSIONS: We provide evidence that disease progression in patients with metastatic breast cancer in a real-world registry has a significant negative impact on HRQoL as measured by MID of HRQoL. This study emphasizes the relevance of avoiding progression and prolonging PFS to maintain QoL.

AB - OBJECTIVES: Improved progression-free survival is considered as treatment goal for patients with metastatic breast cancer (MBC) since it is assumed to delay or prevent deterioration of quality of life. Aim of our analysis was to examine the influence of disease progression on health-related quality of life (HRQoL).MATERIALS AND METHODS: The PRAEGNANT study comprises a real-life registry for patients with MBC. HRQoL was assessed with the EORTC-QLQ-C30 Version 3.0 questionnaire at study entry and every 3 months thereafter. The primary endpoint was minimally important deterioration (MID) in global HRQoL score by ≥ five points between baseline and any follow-up assessment. A logistic regression model was built with MID (yes/no) at a follow-up timepoint as outcome variable and several covariates as predictors.RESULTS: In total, 329 patients were included in this analysis, with disease progression in 63 patients. Concerning the primary study aim, progression status predicted MID of global HRQoL status in addition to the other covariates. The adjusted odds ratio for the effect of progression status on MID was 2.22 (95% CI: 1.04 - 4.73). Comparisons of mean differences of QoL domains/scales yielded no differences.CONCLUSIONS: We provide evidence that disease progression in patients with metastatic breast cancer in a real-world registry has a significant negative impact on HRQoL as measured by MID of HRQoL. This study emphasizes the relevance of avoiding progression and prolonging PFS to maintain QoL.

KW - Journal Article

U2 - 10.1016/j.breast.2017.08.008

DO - 10.1016/j.breast.2017.08.008

M3 - SCORING: Journal article

C2 - 29237546

VL - 37

SP - 154

EP - 160

JO - BREAST

JF - BREAST

SN - 0960-9776

ER -